CD274 and neoplasm: Although the efficacy of cemiplimab in treating multiple KA has not been demonstrated in vivo, immune checkpoint inhibitors targeting PD-1 can block PD-1/PD-L1 interactions, thereby enhancing anti-tumor T-cell responses.